2.25
전일 마감가:
$2.20
열려 있는:
$2.2
하루 거래량:
1.07M
Relative Volume:
0.53
시가총액:
$474.18M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-8.0357
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
-3.43%
1개월 성능:
+9.22%
6개월 성능:
+80.00%
1년 성능:
+73.08%
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ATAI
Atai Life Sciences N V
|
2.25 | 474.18M | 314.00K | -40.23M | -84.71M | -0.28 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-18 | 재확인 | H.C. Wainwright | Buy |
2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
2022-11-01 | 개시 | Loop Capital | Buy |
2021-11-30 | 개시 | Maxim Group | Buy |
2021-11-11 | 개시 | ROTH Capital | Buy |
2021-10-18 | 개시 | H.C. Wainwright | Buy |
2021-09-01 | 개시 | Jefferies | Buy |
2021-07-13 | 개시 | Berenberg | Buy |
2021-07-13 | 개시 | Canaccord Genuity | Buy |
2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
2021-07-13 | 개시 | Citigroup | Buy |
2021-07-13 | 개시 | Cowen | Outperform |
2021-07-13 | 개시 | Credit Suisse | Outperform |
2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.
ATAI’s Stock Dilemma: ATAI Life Sciences N.V’s Market Performance and Outlook - investchronicle.com
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows - investchronicle.com
Atai Life Sciences (ATAI) Garnered a Buy Rating and $12 Target | ATAI Stock News - GuruFocus
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice - Yahoo Finance
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Lucid Capital Markets initiates coverage on atai Life Sciences stock By Investing.com - Investing.com Nigeria
ATAI Gains Buy Rating and Price Target from Lucid Capital | ATAI Stock News - GuruFocus
Lucid Capital Markets initiates coverage on atai Life Sciences stock - Investing.com
ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus
Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance
Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - Morningstar
H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com
Atai in $370M merger deal with psychedelic drug specialist Beckley - BioWorld MedTech
atai Life Sciences (ATAI) Merges with Beckley Psytech for Psyche - GuruFocus
atai Life Sciences and Beckley Psytech merging - Seeking Alpha
Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com
Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg
ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance
ATAI Life Sciences stock soars on Beckley Psytech merger deal By Investing.com - Investing.com UK
Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atai Life Sciences N V 주식 (ATAI) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Kirpekar Sahil | Chief Business Officer |
Mar 21 '25 |
Sale |
1.35 |
48,563 |
65,560 |
115,636 |
Craig Kevin James | Chief Medical Officer |
Mar 21 '25 |
Sale |
1.35 |
11,563 |
15,610 |
8,437 |
Rao Srinivas | See Remarks |
Mar 21 '25 |
Sale |
1.35 |
75,418 |
101,814 |
212,942 |
Johnson Anne Nagengast | Chief Financial Officer |
Mar 21 '25 |
Sale |
1.35 |
33,545 |
45,286 |
140,045 |
Short Glenn Frank | Chief Scientific Officer |
Mar 21 '25 |
Sale |
1.35 |
13,161 |
17,767 |
42,333 |
자본화:
|
볼륨(24시간):